Alzamend Neuro, Inc.
ALZN
$1.89
-$0.03-1.56%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.76% | -4.98% | 6.72% | -11.50% | -31.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.18% | 0.76% | -15.45% | -54.75% | -66.04% |
| Operating Income | -67.18% | -0.76% | 15.45% | 54.75% | 66.04% |
| Income Before Tax | -66.60% | -0.55% | 15.57% | 54.61% | 65.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -66.60% | -0.55% | 15.57% | 54.61% | 65.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.60% | -0.55% | 15.57% | 54.61% | 65.92% |
| EBIT | -67.18% | -0.76% | 15.45% | 54.75% | 66.04% |
| EBITDA | -66.92% | -0.25% | 15.76% | 55.03% | 66.34% |
| EPS Basic | 83.48% | 90.39% | 90.73% | 85.69% | 83.49% |
| Normalized Basic EPS | 86.44% | 91.87% | 91.64% | 86.36% | 83.53% |
| EPS Diluted | 83.48% | 90.39% | 90.73% | 85.69% | 83.49% |
| Normalized Diluted EPS | 86.44% | 91.87% | 91.64% | 86.36% | 83.53% |
| Average Basic Shares Outstanding | 757.74% | 976.56% | 1,120.60% | 498.94% | 294.12% |
| Average Diluted Shares Outstanding | 757.74% | 976.56% | 1,120.60% | 498.94% | 294.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |